問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Psychiatry

Division of Pediatrics

更新時間：2023-09-19

黃玉書Huang, Yu-Shu
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • az1109@cgmh.org.tw

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃玉書

List

10Cases

2009-06-01 - 2017-08-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-03-15 - 2025-05-15

Phase III

Active
An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090

  • Condition/Disease

    Retinopathy of Prematurity (ROP)

  • Test Drug

    Eylea

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-01-02 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-03-15 - 2008-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-12-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-08-01 - 2015-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

2011-11-01 - 2014-08-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2015-10-01 - 2019-08-31

Phase III

An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD

  • Condition/Disease

    Attention Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    ORADUR®-Methylphenidate

Participate Sites
3Sites

Terminated3Sites

2015-06-01 - 2017-02-28

Phase III

A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD

  • Condition/Disease

    ADHD (Attention Deficit Hyperactivity Disorder)

  • Test Drug

    ORADUR-Methylphenidate

Participate Sites
4Sites

Terminated4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB